SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Eureka Acquisition Corp entered into a material definitive agreement with Marine Thinking to effect a business combination, including the issuance of an unsecured promissory note (Extension Note) for $150,000 to fund a one-month extension of the business combination deadline, with conversion rights into private units upon completion of the merger.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Purple Innovation's Annual Meeting held on June 9, 2026. The filing presents detailed vote tallies for three proposals: election of eight directors, advisory approval of named executive officer compensation, and ratification of BDO USA, LLP as independent auditor. Item 5.07 is the designated 8-K item for shareholder vote results, and the prose directly reports the voting outcomes with vote counts for each director and proposal.
View raw filing on EDGAR →BlockchAIn Digital Infrastructure completed a public offering of 33,333,334 shares at $1.65 per share on June 8, 2026, raising approximately $51.4 million in net proceeds and issuing 1,333,333 Representative Warrants to the underwriter. This substantial equity issuance represents a material dilutive capital raise affecting existing shareholder ownership and the company's financial position.
View raw filing on EDGAR →Getty Images discloses an adverse court decision in Funicular Funds LP v. Getty Images Holdings, Inc., with the court granting summary judgment to plaintiffs on warrant breach claims and directing entry of judgment for approximately $67.8 million plus pre-judgment interest. This material litigation outcome—a judicial determination of liability and damages—directly affects the company's financial position and has been reserved against on the balance sheet, making it a significant material event requiring disclosure under Item 8.01.
View raw filing on EDGAR →The filing discloses Item 5.07 results from Ramaco Resources' Annual Meeting of Shareholders held on June 10, 2026, including voting outcomes on four proposals: election of three directors (Bryan H. Lawrence, David E.K. Frischkorn Jr., and Michael R. Graney), ratification of Grant Thornton LLP as independent auditor, approval of a 4,000,000-share increase to the Long-Term Incentive Program, and advisory approval of named executive officer compensation. All proposals passed with substantial majorities, representing material governance and compensation decisions.
View raw filing on EDGAR →The filing discloses that Ribbon Acquisition Corp. regained compliance with Nasdaq Listing Rule 5250(f) following payment of a past due fee balance, resolving a non-compliance matter previously disclosed on June 5, 2026. While the company has now cured the violation, the disclosure of a listing rule breach and its resolution is material to investors assessing continued listing status and regulatory standing. The delisting_risk classification captures the materiality of listing compliance events, even when resolved.
View raw filing on EDGAR →The disclosure announces a postponement of the extraordinary general meeting scheduled to vote on a proposed business combination between M3-Brigade Acquisition V Corp. and ReserveOne, Inc., moving the vote from June 15 to June 18, 2026, and extending the shareholder redemption deadline. While this is a material event affecting shareholders' ability to vote on and redeem shares in connection with a significant M&A transaction, it is procedural in nature (a meeting postponement) rather than a substantive change to the business combination itself. The event does not fit neatly into the ma_activity category (which covers entry, completion, or termination of M&A) or shareholder_vote_results (which covers actual vote outcomes), making other_material the most appropriate classification.
View raw filing on EDGAR →The filing discloses an extension of byNordic's business combination deadline from June 12, 2026 to July 12, 2026, funded by a $17,470 deposit into the Trust Account. This is a material event for a SPAC as it directly affects the timeline for completing the initial business combination and the company's continued existence. While not a traditional M&A completion, the extension is a critical milestone event that would affect investor assessment of the registrant's prospects and timeline.
View raw filing on EDGAR →The filing discloses an unregistered sale of limited partnership units totaling approximately $89.55 million under Item 3.02, with Class I and Class E units sold to accredited investors and qualified purchasers pursuant to Section 4(a)(2) and Regulation D. This is a classic dilutive equity issuance by a fund that would materially affect existing unitholders' ownership percentages and is a core disclosure event for private fund offerings.
View raw filing on EDGAR →Aditxt entered into a Business Combination Agreement dated June 10, 2026, whereby its subsidiary Ignite Proteomics LLC will merge with Copley Acquisition Corp (SPAC) in a two-step transaction resulting in Ignite becoming a wholly-owned subsidiary of the resulting public company (Pubco), with merger consideration of $150 million in Pubco common stock.
View raw filing on EDGAR →Presidio Production Company entered into a material definitive agreement on June 9, 2026, whereby its subsidiary Presidio Finance LLC issued $350 million in aggregate principal amount of asset-backed securities (ABS III Notes) in a private offering under Section 4(a)(2). While this is technically a debt issuance rather than a traditional M&A transaction, the Item 1.01 classification and the materiality of the $350 million financing—which refinances existing debt and provides capital for general corporate purposes—makes this a material capital structure event. The transaction involves entry into a definitive indenture agreement governing the ABS III Notes and represents a significant financing activity material to investors.
View raw filing on EDGAR →The filing discloses the appointment of Erik Blum as President effective June 1, 2026, with a detailed employment agreement specifying $200,000 base salary, $50,000 restricted stock grant, and up to 20% performance bonus. While the section also mentions Patricia Kaelin's dismissal as CFO, the primary focus and substantive disclosure centers on Blum's appointment and compensatory arrangements. This is material as it represents a significant executive appointment with detailed compensation terms affecting the company's leadership structure.
View raw filing on EDGAR →EBR Systems entered into an underwriting agreement for a fully underwritten A$150.0 million capital raise through the sale of approximately 394.7 million new CDIs (representing new shares) to institutional and retail investors on the ASX, comprising an institutional placement and pro rata entitlement offer that will dilute existing shareholders.
View raw filing on EDGAR →The filing explicitly discloses an "Earnings Release announcing its Fiscal 2026 fourth quarter and year-end financial results for the quarter and year ended March 31, 2026" under Item 2.02 (Results of Operations and Financial Condition), with the release attached as Exhibit 99.1. This is a standard earnings release disclosure.
View raw filing on EDGAR →This Item 5.07 disclosure presents the results of ImmunityBio's 2026 Annual Meeting of Stockholders held on June 9, 2026, including voting outcomes for the election of nine directors and ratification of Deloitte & Touche LLP as independent auditor. The filing directly matches the shareholder_vote_results event type, which covers results of votes at annual or special meetings of security holders. These outcomes are material to investors as they confirm the composition of the board and auditor selection.
View raw filing on EDGAR →Crocs held its Annual Meeting of Stockholders on June 9, 2026, with shareholders voting on four matters: election of Class III directors (Smach, Kaplan, Tolmare), ratification of Deloitte & Touche LLP as auditor, advisory approval of named executive officer compensation, and approval of the 2026 Equity Incentive Plan. All proposals passed with substantial majorities.
View raw filing on EDGAR →Craig Saldanha resigned as Chief Product Officer after four years in the role, representing a departure of a named executive officer in a C-suite position.
View raw filing on EDGAR →Yelp held its Annual Meeting of Stockholders on June 5, 2026, with certified voting results on four proposals: election of nine directors, ratification of Deloitte & Touche LLP as independent auditor, advisory approval of named executive officer compensation, and approval of the Restated ESPP.
View raw filing on EDGAR →Kiora Pharmaceuticals held its Annual Meeting on June 10, 2026, with shareholders voting on four proposals: election of three Class II Directors (Lisa Walters-Hoffert, Aron Shapiro, and Praveen Tyle, Ph.D.), a non-binding advisory vote on named executive officer compensation, ratification of Haskell & White LLP as independent auditor, and approval of a 1,500,000 share increase to the 2024 Equity Incentive Plan. All four proposals passed.
View raw filing on EDGAR →The disclosure centers on the Board's approval and appointment of Todd Diganci as a director effective August 1, 2026, expanding the Board from nine to ten members. While the section also mentions standard director compensation arrangements, the principal disclosed action is the appointment of a new director with significant financial and regulatory experience (former FINRA EVP/CFO/CAO), making this an exec_appointment event. The appointment is material as it affects Board composition and governance.
View raw filing on EDGAR →This is Item 5.07 disclosing the final voting results from Aquestive Therapeutics' 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing presents tabulated results for three matters: election of Class II directors (Gregory B. Brown, John S. Cochran, and Abigail L. Jenkins), advisory approval of executive compensation, and ratification of KPMG LLP as independent auditor. This is a standard shareholder vote results disclosure that is material to investors as it confirms governance outcomes and auditor appointment.
View raw filing on EDGAR →The disclosure announces commencement of field operations for a planned sidetrack phase of the Megiddo-Jezreel #2 well in Israel, including re-entry, drilling out a temporary plug, wellbore conditioning, and horizontal sidetrack drilling. While this represents a material operational milestone for an exploration company with active petroleum operations, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A activity, impairment, or other defined event types). The operational progress on a material exploration project would affect a reasonable investor's assessment of the company's execution and prospects.
View raw filing on EDGAR →CervoMed entered into a securities purchase agreement for a private placement of 3,360,377 units comprising common stock (or pre-funded warrants) and Series B and C warrants, generating approximately $10.5 million in gross proceeds with potential additional $21.7 million upon warrant exercise. The unregistered securities are subject to resale restrictions, with significant insider participation from the CEO, Chair, and Director. Proceeds will be used for R&D and operations.
View raw filing on EDGAR →CervoMed disclosed entry into a Purchase Agreement and provided business updates via press release on June 10, 2026, including Strategic Pipeline Priorities. The specific terms and financial impact of the Purchase Agreement are not detailed in the filing excerpt, preventing confident classification as a more specific event type such as M&A activity.
View raw filing on EDGAR →The Company is announcing an irrevocable election to redeem outstanding warrants (CUSIP # 74587B143) issued in a July 2024 rights offering. The redemption is triggered by the stock price reaching 200% of the exercise price ($22.00) for 20 consecutive trading days, with warrants redeemable for $0.01 per share by July 13, 2026. While this is a warrant redemption event that affects security holders, it does not fit neatly into the more specific categories (not a dilutive issuance, not M&A, not an impairment). The event is material as it affects the rights and economic interests of warrant holders and the capital structure of the Company.
View raw filing on EDGAR →Orchid Island Capital held its 2026 Annual Meeting of Stockholders with voting results on four proposals: election of six directors, ratification of BDO USA as independent auditor, advisory approval of named executive officer compensation, and advisory frequency recommendation for future compensation votes.
View raw filing on EDGAR →The company announced a monthly dividend of $0.10 per share and disclosed portfolio details as of May 31, 2026, including RMBS portfolio information and other operational metrics.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from the 2026 annual meeting held on June 10, 2026. The filing reports voting outcomes on three matters: election of Class II directors (Michael Earley and Veronica Hill-Milbourne), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the hallmark of shareholder_vote_results classification.
View raw filing on EDGAR →ImmuCell's Board authorized a significant manufacturing capacity expansion program involving ~$3.5 million in Phase 1 capital investment and strategic repurposing of facilities to shift from Re-Tain® to First Defense® production. This represents a material strategic and operational decision affecting the company's manufacturing footprint and capital allocation, but does not fit neatly into the standard 8-K event taxonomy (not M&A, not an impairment, not an executive change). The disclosure is material to investors assessing the company's growth strategy and capital deployment.
View raw filing on EDGAR →Item 2.02 is the standard location for disclosure of quarterly or annual financial results. The filing date of 2026-06-10 and Item 2.02 designation indicate this section contains an earnings release or results of operations disclosure, which is material to investors' assessment of the company's financial performance.
View raw filing on EDGAR →Molina Healthcare announced that the Illinois Department of Healthcare and Family Services intends to award a HealthChoice Illinois Medicaid Managed Care program contract to its Illinois subsidiary. This is a material contract award that would affect the registrant's revenue and business operations, but it does not fit neatly into the standard M&A, earnings, or executive event categories. The disclosure is made under Regulation FD (Item 7.01), indicating it is material information being disclosed to investors.
View raw filing on EDGAR →Usio held its Annual Meeting of Stockholders on June 10, 2026, with voting results on three proposals: election of two Class III directors (Ernesto R. Beyer and Bradley Rollins), advisory vote on executive compensation, and ratification of Withum Smith+Brown, P.C. as independent auditor.
View raw filing on EDGAR →MIND Technology issued a press release on June 10, 2026 announcing financial results for the fiscal quarter ended April 30, 2026, furnished as Exhibit 99.1.
View raw filing on EDGAR →The Company entered into Amendment No. 2 to its credit agreement, extending the maturity of its revolving credit facility to June 5, 2031, expanding borrowing capacity options, and relaxing financial covenants including an increase in the Consolidated Net Leverage Ratio threshold from 3.00:1.00 to 3.50:1.00.
View raw filing on EDGAR →Michael A. Pollner, Senior Vice President, General Counsel & Secretary, provided notice of resignation effective June 30, 2026.
View raw filing on EDGAR →BIO-key received formal notice from Nasdaq on June 5, 2026, that it failed to satisfy Nasdaq Listing Rule 5250(c)(1) by not filing its Form 10-Q for the period ended March 31, 2026. The notice explicitly states this serves as an additional basis for delisting and that a Nasdaq Hearing Panel will determine the Company's continued listing status.
View raw filing on EDGAR →Pacific Oak Strategic Opportunity REIT entered into a court-approved debt restructuring arrangement affecting Series B and Series D bonds (totaling approximately NIS 975 million) issued by its BVI subsidiary, along with a related Second Loan funding agreement. This restructuring fundamentally alters the capital structure, maturity, interest rates, security interests, and operational control of the subsidiary.
View raw filing on EDGAR →On June 4, 2026, Agassi Sports Entertainment Corp. entered into a material definitive license agreement granting it exclusive rights to use Darren Cahill's name, likeness, voice, image, and personality in connection with its "Darren AI" platform and broader sports entertainment business for a 15-year term with automatic renewals. The agreement provides consideration of 250,000 warrants at $5.00/share, representing a significant strategic asset acquisition for the Company's core business operations.
View raw filing on EDGAR →KIDZ AI Inc. held its annual stockholder meeting on June 10, 2026, with shareholders voting on five proposals: approval of increased Class B authorized shares, issuance of shares to Solana Growth Ventures LLC, reverse stock split authorization, sale of Class A shares to CEO Hui Luo, and election of five directors. The filing discloses the tabulated voting results for each proposal.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from OFS Capital's 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing reports voting outcomes for two matters: (1) election of two Class II directors (Romita Shetty and Bilal Rashid), and (2) ratification of KPMG LLP as independent auditor. The detailed voting tallies (For, Against, Withheld, Abstain, Broker Non-Votes) are provided for each proposal, which is the hallmark of Item 5.07 disclosure.
View raw filing on EDGAR →The filing discloses the appointment of Dr. Clemens as Chief Financial Officer, announced via press release on June 10, 2026. This is a material executive appointment to a named officer position (CFO), which would affect a reasonable investor's assessment of the company's leadership and financial oversight.
View raw filing on EDGAR →The filing explicitly addresses the company's previously disclosed substantial doubt regarding going concern. Management states that the availability of WLFI token holdings "materially strengthens the Company's liquidity profile and addresses a significant factor underlying the going concern disclosure contained in the Company's most recent Quarterly Report on Form 10-Q," and concludes that "the conditions that gave rise to the previously disclosed substantial doubt regarding the Company's ability to continue as a going concern have been substantially mitigated." This is a material update to a critical going-concern issue.
View raw filing on EDGAR →The 8-K discloses a press release announcing the Company's annual shareholder letter for the fiscal year ended March 31, 2026, filed under Item 7.01 (Regulation FD Disclosure). While the actual press release content is not provided in the extractable text, the disclosure of annual financial results via shareholder letter constitutes an earnings release, which is material to investors' assessment of the registrant's financial performance and condition.
View raw filing on EDGAR →The filing discloses that MicroVision "issued a press release announcing the signing of a Master Development Agreement, including an initial Program Description dated June 1, 2026." A Master Development Agreement represents a material strategic partnership or collaboration arrangement. While the full details are in the attached press release (Exhibit 99.1), the disclosure of a signed master development agreement with an initial program description constitutes a material business development event that would affect investor assessment of the company's growth prospects and strategic direction.
View raw filing on EDGAR →The 8-K discloses that Eva Live Inc. signed a letter of intent to acquire Psquared, an AI-powered performance marketing platform, in a transaction valued at $1 trillion in the digital ad market. This constitutes entry into a material acquisition transaction, which is a reportable event under Item 8.01 (Other Events) and Item 1.01 (Business Combinations). The acquisition of a platform in a major market segment would materially affect investor assessment of the company's strategic direction and financial position.
View raw filing on EDGAR →The filing discloses execution of a "Development Services Agreement to Build AI-Powered Used Mobile Phone Sales Agent" on June 8, 2026. While the agreement itself is material (a strategic development contract), the disclosure lacks sufficient detail to classify it as a specific M&A activity, material contract, or other defined event type. The redacted agreement and press release suggest a significant business development, but without clarity on financial terms, duration, or strategic impact, this is best classified as other_material rather than forcing it into a more specific category.
View raw filing on EDGAR →The filing discloses an unregistered sale of 1,103,338 shares of common stock at $0.72 per share for aggregate gross proceeds of $794,403 to foreign accredited investors under Regulation S. Item 3.02 explicitly confirms this is an unregistered equity issuance. The transaction is material as it represents a dilutive equity raise and requires ongoing registration obligations under the Registration Rights Agreement.
View raw filing on EDGAR →The filing discloses results of Figure Technology Solutions' Annual Meeting of Stockholders held on June 4, 2026, under Item 5.07. It reports voting outcomes for two proposals: (1) election of eight directors with detailed vote tallies for each nominee, and (2) ratification of KPMG LLP as independent auditor. These are standard shareholder vote results that materially inform investors about board composition and audit oversight.
View raw filing on EDGAR →M2i Global received a termination notice from Volato Group purporting to terminate the "Agreement and Plan of Merger Reorganization" dated July 28, 2025. Although the Company disputes the termination and asserts it has complied with its obligations, this disclosure concerns the termination or attempted termination of a material merger transaction—a core M&A activity. The Company's statement that it "intends to vigorously enforce its contractual rights and pursue all available remedies" confirms the materiality and contested nature of this merger termination event.
View raw filing on EDGAR →Figure Technology Solutions entered into an Agreement and Plan of Merger on June 10, 2026, to acquire Kiavi, Inc. for $532.426 million in cash consideration (Item 1.01). The filing discloses a material definitive merger agreement with customary closing conditions, termination rights, and a $25 million termination fee, along with a $600 million bridge financing commitment. This is a classic material acquisition transaction.
View raw filing on EDGAR →